Prostate cancer: role of SPECT and PET in imaging bone metastases.
暂无分享,去创建一个
[1] I. Fogelman,et al. Bone scanning in clinical oncology: does it have a future? , 1998, European Journal of Nuclear Medicine.
[2] H D Humes,et al. Carbon-11-acetate PET imaging in renal disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] R. Wahl,et al. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. , 1996, Nuclear medicine and biology.
[4] Sven Perner,et al. Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of Nuclear Medicine.
[5] H. Scher,et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of Clinical Oncology.
[6] P. Shreve,et al. Imaging of the pancreas and related diseases with PET carbon-11-acetate. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] I. Fogelman,et al. The role of nuclear medicine in monitoring treatment in skeletal malignancy. , 2001, Seminars in nuclear medicine.
[8] G. V. von Schulthess,et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.
[9] S. Kosuda,et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] P. Waldenberger,et al. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT , 2009, Molecular Imaging and Biology.
[11] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[12] J. Bergh,et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT , 1998, Skeletal Radiology.
[13] Gopal Singh,et al. Regulation of prostate cancer cell division by glucose , 1999, Journal of cellular physiology.
[14] J. Mckillop. Bone Scanning in Metastatic Disease , 1987 .
[15] P. Cutler,et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] J. Oesterling,et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.
[17] R. Tiguert,et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. , 2002, The Journal of urology.
[18] K. Pienta,et al. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. , 1998, Journal of the National Cancer Institute.
[19] H. Schirrmeister,et al. Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study , 2004, BMJ : British Medical Journal.
[20] R. Coleman,et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] S. Rosenthal,et al. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. , 1996, Clinical nuclear medicine.
[22] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[23] J. Barrio,et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[25] H. Schirrmeister,et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[26] P. Davidson,et al. Should mass screening for prostate cancer be introduced at the national level , 2004 .
[27] M. Noguchi,et al. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment , 2003, BJU international.
[28] Kenneth H. Wong,et al. Progress in SPECT/CT Imaging of Prostate Cancer , 2006, Technology in cancer research & treatment.
[29] S. Larson,et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. , 1996, Nuclear medicine and biology.
[30] Nobuyuki Oyama,et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] Josef Hammer,et al. The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT , 2010, Molecular Imaging and Biology.
[32] R E O'Mara,et al. Skeletal scanning in neoplastic disease , 1976, Cancer.
[33] M. Banerjee,et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.
[34] G Jakse,et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.
[35] U. Haberkorn,et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] K. Ishiwata,et al. Increased amounts of D-enantiomer dependent on alkaline concentration in the synthesis of L-[methyl-11C]methionine. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[37] Eduard Schreibmann,et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[39] T. Hara,et al. PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] P. Schellhammer,et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.
[41] A. Alavi,et al. Implications of PET based molecular imaging on the current and future practice of medicine. , 2004, Seminars in nuclear medicine.
[42] V. Canzonieri,et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[43] G. Grasselli,et al. The role of bone SPET study in diagnosis of single vertebral metastases. , 2000, Anticancer research.
[44] J. Oesterling,et al. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. , 1997, The Urologic clinics of North America.
[45] P. Scalliet,et al. Metastases Seen on SPECT Imaging Despite a Normal Planar Bone Scan , 1995, Clinical nuclear medicine.
[46] N. Clarke,et al. bone marrow endothelium: binding , 2022 .
[47] R. Rubens,et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] M. Blau,et al. Fluorine-18: a new isotope for bone scanning. , 1962, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[50] I. Fogelman,et al. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.
[51] F DuBois Bowman,et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[52] A. Belldegrun,et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. , 1999, The Journal of urology.
[53] Mj Callanan,et al. Location of I , 2007 .
[54] Ora Israel,et al. Positron emission tomography and bone metastases. , 2005, Seminars in nuclear medicine.
[55] I. Fogelman,et al. The role of positron emission tomography in the management of bone metastases , 2000, Cancer.
[56] David Verbel,et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. , 2002, Urology.
[57] J. Pruim,et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] Mary Ann Moran,et al. Synthesis and Evaluation , 1986 .
[59] A. Partin,et al. Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.
[60] R. Wahl,et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.
[61] A. Ochiai,et al. Prostate‐specific antigen induces apoptosis of osteoclast precursors: Potential Role in osteoblastic bone metastases of prostate cancer , 2006, The Prostate.
[62] G. F. Gates,et al. SPECT bone scanning of the spine. , 1998, Seminars in nuclear medicine.
[63] M. Endo,et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. , 2005, AJR. American journal of roentgenology.
[64] J Kotzerke,et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[65] Nobuyuki Oyama,et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] S Noda,et al. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer , 2003, British Journal of Cancer.
[67] M. Koizumi,et al. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. , 1999, Clinical nuclear medicine.
[68] I. Sesterhenn,et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] J. Texter,et al. The role of monoclonal antibody in the management of prostate adenocarcinoma. , 1998, The Journal of urology.
[70] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[71] T. Hara,et al. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[72] P. Valk,et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] S M Larson,et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] Joonyoung Kim,et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. , 2003, Bioconjugate chemistry.
[75] D. Bostwick,et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.
[76] Y. Erdi,et al. Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .
[77] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] E. Bombardieri,et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[79] R. Coleman,et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[80] George L. Wright,et al. Location of prostate‐specific membrane antigen in the LNCaP prostate carcinoma cell line , 1997, The Prostate.
[81] Mithat Gonen,et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] R. Babaian,et al. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. , 1994, The Journal of urology.
[83] J. Oesterling,et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. , 1991, The Journal of urology.
[84] I. Fogelman,et al. Skeletal Nuclear Medicine , 1996 .
[85] D. Rosenthal. Radiologic diagnosis of bone metastases , 1997, Cancer.
[86] A. Sbarbati,et al. De novo synthesis of diacylglycerol from glucose. A new pathway of signal transduction in human neutrophils stimulated during phagocytosis of beta-glucan particles. , 1991, The Journal of biological chemistry.
[87] N. Kosaka,et al. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. , 1999, Cancer.
[88] T. Au-yong,et al. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain , 1998, European Journal of Nuclear Medicine.
[89] M. Beheshti,et al. [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[90] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[91] Z. Lengyel,et al. Detection of prostate cancer with 11C-methionine positron emission tomography. , 2005, The Journal of urology.
[92] P. Valk,et al. Cost-effectiveness of PET imaging in clinical oncology. , 1996, Nuclear medicine and biology.
[93] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[94] C. Dence,et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[95] Z. Dotan. Bone imaging in prostate cancer , 2008, Nature Clinical Practice Urology.
[96] C. Cordon-Cardo,et al. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. , 1998, Cancer research.
[97] Shankar Vallabhajosula,et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] J. Richter,et al. PET and prostate cancer , 2004, World Journal of Urology.
[99] T. Hara,et al. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[100] S. Vallabhajosula,et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] M. Reiser,et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. , 1999, Journal of computer assisted tomography.
[102] P. Waldenberger,et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[103] Sven N. Reske,et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[104] M. Timins,et al. Diagnostic bone scanning in oncology. , 1997, Seminars in nuclear medicine.
[105] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[106] R. Coleman,et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. , 2001, Cancer research.
[107] L. Mortelmans,et al. FDG-PET: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[108] Ryan Park,et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[109] J. Pruim,et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[110] Philippe Massin,et al. [Pathophysiology of bone metastases]. , 2003, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[111] Michael J. Morris,et al. 11C-acetate PET imaging in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[112] G. Hutchins,et al. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. , 2004, Bioorganic & medicinal chemistry.
[113] G H Hinkle,et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide , 1998, Cancer.
[114] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[115] W P Segars,et al. Fast modelling of the collimator–detector response in Monte Carlo simulation of SPECT imaging using the angular response function , 2005, Physics in medicine and biology.
[116] H. Biersack,et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[117] S. Suciu,et al. Do bone scans predict prognosis in prostatic cancer? A report of the EORTC protocol 30762. , 1984, British journal of urology.
[118] Robert H. Martin,et al. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. , 1993, Radiology.
[119] M J Welch,et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.
[120] S. Larson,et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] R. Franklin,et al. Citrate metabolism of normal and malignant prostate epithelial cells. , 1997, Urology.
[122] H. Miyazawa,et al. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[123] H. Saji,et al. Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[124] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] M. Choueiri,et al. The central role of osteoblasts in the metastasis of prostate cancer , 2007, Cancer and Metastasis Reviews.
[126] J. Moul,et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.
[127] R. Miralbell,et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[128] M. Kattan,et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] N. Shinoura,et al. PET imaging of brain tumor with [methyl-11C]choline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[130] M. Morris,et al. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* , 2008, Journal of Nuclear Medicine.